ES8405026A1 - Tylosin derivs. - Google Patents

Tylosin derivs.

Info

Publication number
ES8405026A1
ES8405026A1 ES520907A ES520907A ES8405026A1 ES 8405026 A1 ES8405026 A1 ES 8405026A1 ES 520907 A ES520907 A ES 520907A ES 520907 A ES520907 A ES 520907A ES 8405026 A1 ES8405026 A1 ES 8405026A1
Authority
ES
Spain
Prior art keywords
alkyl
group
opt
substd
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES520907A
Other languages
Spanish (es)
Other versions
ES520907A0 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microbial Chemistry Research Foundation
Original Assignee
Microbial Chemistry Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbial Chemistry Research Foundation filed Critical Microbial Chemistry Research Foundation
Priority to ES520907A priority Critical patent/ES520907A0/en
Publication of ES8405026A1 publication Critical patent/ES8405026A1/en
Publication of ES520907A0 publication Critical patent/ES520907A0/en
Granted legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

EP--70170 A Tylosin derivs. of formula (I) are new. (R1 is OH, halogen, NR5R6, NX (opt. substd. by an oxo gp., OH, 1-6C alkyl or 1-6C hydroxyalkyl), or imidazolyl, morpholino or piperazino (each opt. substd. by 1-6C alkyl) or O-COCH2R8; R5 is H or 1-6C alkyl opt. substd. by a OH gp.; R6 is H, 1-6C alkyl opt. substd. by a OH gp., aryl, aralkyl, 3-10C cycloalkyl, CO(O)mR7 or CH2R13; m is 0 or 1; R7 is 1-6C alkyl, aryl, aralkyl, furaryl or pyridinyl; R13 is CH2F, CHF2 or CF3; X is (CH2)n; n is 2-15; R8 is NR9R10 or SR11; R9 and R10 are H or 1-6C alkyl; or R9 + R10 form 3-7C alkylene; R11 is furanyl or pyridinyl; R2 is H or 1-6C alkanoyl; R3 is Me or CH2CHO; R4 is H or OH; A is O, (alpha H, beta OH) or (alpha OH, beta H); the wavy line is a single or double bond; and the broken line is a single or double bond or an epoxy-bridged single bond. Provided that (1) when R1 is OH, R3 is Me and R4 is H, or the broken line is an epoxy-bridged single bond; and (2) when R1 is halogen, R3 is Me or the broken line is an epoxy-bridged bond). - (I) are broad-spectrum antibacterials with greater activity then tylosin. Dose is 0.01-1 g administered 1-4 times daily. EPAB- EP--70170 B Tylosin derivs. of formula (I) are new. (R1 is OH, halogen, NR5R6, NX (opt. substd. by an oxo gp., OH, 1-6C alkyl or 1-6C hydroxyalkyl), or imidazolyl, morpholino or piperazino (each opt. substd. by 1-6C alkyl) or O-COCH2R8; R5 is H or 1-6C alkyl opt. substd. by a OH gp.; R6 is H, 1-6C alkyl opt. substd. by a OH gp., aryl, aralkyl, 3-10C cycloalkyl, CO(O)mR7 or CH2R13; m is 0 or 1; R7 is 1-6C alkyl, aryl, aralkyl, furaryl or pyridinyl; R13 is CH2F, CHF2 or CF3; X is (CH2)n; n is 2-15; R8 is NR9R10 or SR11; R9 and R10 are H or 1-6C alkyl; or R9 + R10 form 3-7C alkylene; R11 is furanyl or pyridinyl; R2 is H or 1-6C alkanoyl; R3 is Me or CH2CHO; R4 is H or OH; A is O, (alpha H, beta OH) or (alpha OH, beta H); the wavy line is a single or double bond; and the broken line is a single or double bond or an epoxy-bridged single bond. Provided that (1) when R1 is OH, R3 is Me and R4 is H, or the broken line is an epoxy-bridged single bond; and (2) when R1 is halogen, R3 is Me or the broken line is an epoxy-bridged bond). - (I) are broad-spectrum antibacterials with greater activity then tylosin. Dose is 0.01-1 g administered 1-4 times daily. (177pp) - EP--70170 B A tylosin derivative represented by the general formula (I) wherein R1 represents NR5R6 (wherein R5 represents a hydrogen atom or a C1 to C6 alkyl group which may be substituted by a hydroxyl group and R6 represents a hydrogen atom, a C1 to C6 alkyl group which may be substituted by a hydroxyl group, an aryl group, an aralkyl group, a cycloalkyl group having 3-10 carbonatoms, -CO(O)m-R7 (wherein m represents 0 or 1 and R7 represents a C1- to C6 alkyl group, an aryl group, an aralkyl group, a furanyl group or a pyridyl group), or -CH2-R13 (wherein R13 represents a mono-, di-, or trifluoromethyl group)); gp. (a) (wherein n represents an integer of 2-15) and which may be substituted by an oxo, a hydroxyl group, A C1 to C6 alkyl group, or a hydroxy C1 to C6 alkyl group; or an imidazolyl, morpholino, or piperazino group which may each be substituted by a C1 to C6 alkyl group; R2 represents a hydrogen atom or a C1 to C6 alkanoyl group; R3 represents a methyl or -CH2CHO group; R4 represents a hydrogen atom or a hydroxyl group; A represents O=, (b) or (c); wavy line reprsents a single or double bond; and dotted line represents a single, a double bond, or (d) provided that when R1 is a hydroxyl group, R3 is a methyl group and R4 is hydrogen atom or said dotted line is (d), and that when R1 is halogen atom, R3 is methyl group or dotted line is (d). (151pp) USAB- US4477443 A Tylosin cpds. of formula (I) are new. In the formula, R1 or OH, halo, NR5R6, cyclic C(CH2)n which is opt. substd. or OOCCH2R8. R5 is H, alkyl or hydroxyalkyl, R6 is as for R5, aryl, aralkyl, cycloalkyl, etc. n is 2-15. R8 is NR9R10 in which R9 is R10 are H or alkyl or combine to form 3-7C alkylene gp., or is S-R11 in which R11 is furanyl or pyridyl. R2 is H or alkanoyl R3 is CH3 or CH2CHO. R4 is is H or OH. A is O, H and OH is either configuration. The dotted bond is opt. present. X is O, 2H or is absent such that a second CC bond is formed. When R1 is OH, R3 os CH3 and R4 is H or X is O. When R1 is halo, R3 is CH3 or X is O.
ES520907A 1983-03-23 1983-03-23 A METHOD FOR THE PREPARATION OF A THYLOSINE DERIVATIVE. Granted ES520907A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES520907A ES520907A0 (en) 1983-03-23 1983-03-23 A METHOD FOR THE PREPARATION OF A THYLOSINE DERIVATIVE.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES520907A ES520907A0 (en) 1983-03-23 1983-03-23 A METHOD FOR THE PREPARATION OF A THYLOSINE DERIVATIVE.

Publications (2)

Publication Number Publication Date
ES8405026A1 true ES8405026A1 (en) 1984-05-16
ES520907A0 ES520907A0 (en) 1984-05-16

Family

ID=8485508

Family Applications (1)

Application Number Title Priority Date Filing Date
ES520907A Granted ES520907A0 (en) 1983-03-23 1983-03-23 A METHOD FOR THE PREPARATION OF A THYLOSINE DERIVATIVE.

Country Status (1)

Country Link
ES (1) ES520907A0 (en)

Also Published As

Publication number Publication date
ES520907A0 (en) 1984-05-16

Similar Documents

Publication Publication Date Title
NL930136I1 (en) Propenylamines methods for their preparation of pharmaceutical preparations containing them and their use as pharmaceuticals
NO307053B1 (en) O-alkylated rapamycin derivatives as well as pharmaceutical preparations containing the derivatives
ES8308333A1 (en) Tylosin derivatives, their preparation and pharmaceutical compositions containing them.
SE8801515D0 (en) PHARMACEUTICAL COMPOSITION
GB1437912A (en)
ES8405027A1 (en) Tylosin derivs.
ES8405029A1 (en) Tylosin derivs.
ES8405026A1 (en) Tylosin derivs.
ZA75463B (en) Derivatives of the n-<eta-4'-(3"-indolyl) piperidino) alkyl> benzamides their salts process for preparing them and pharmaceutical compositions
ATE38028T1 (en) CYCLOALIPHATIC MEDICINAL COMPOSITIONS.
GB1317773A (en) Method of reducing sebum production
GB1274652A (en) Adamantanyl-alkylamine derivatives and their preparation
GB1206790A (en) Organo-silicon complexes and preparation thereof
DE3062201D1 (en) Antimycotic compositions containing imidazolylenol ethers, their preparation and their use
GB1064928A (en) Basic ethers and preparation thereof
GB1122249A (en) Novel diazo compounds and diazotype copying material
ES8201563A1 (en) Morpholine derivatives, process for their production, pharmaceutical preparations containing these derivatives.
HK26877A (en) An ether of 1-(2-hydroxyethyl)-3-methyl-pyrazolin-5-one processes for its preparation and its use as an antithrombotic agent
ES8507123A1 (en) 4-alkyl-2-hydroxy-3-methyl-2-phenyl-morpholine derivatives, process for their preparation and their therapeutical use
EE9800134A (en) Pharmaceutical composition for intravenous administration
ES8604970A1 (en) 2-Tetrazolylpropyl-2-penem derivatives, process for their preparation, pharmaceutical compositions containing them and their use.
GB979680A (en) Pharmaceutical compositions containing esters of quaternary atropinium salts
GB978095A (en) Substituted benzamides having tranquillizing activity
ES8603429A1 (en) N-bicycloheptyl- and N-bicycloheptenyl imidazoles, process for their preparation, use and pharmaceutical preparations.
ES464751A1 (en) F3-phenoxy-n-substituted morphinan derivatives their manufacture and pharmaceutical preparations containing them